Physician profile
Manmohan Gupta
NPI 1467569681
$6,887.65
in general payments reported to CMS, 2019-2025
29 companies · $461 in 2025
The $461 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $1,099 · 2021: $870 · 2022: $1,382 · 2023: $1,148 · 2024: $573 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,111 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,111.19 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,325.37 | 2019-2025 | |
| Janssen Biotech, INC. | $865.25 | 2019-2025 | Tremfya, Simponi, Stelara |
| Ucb, INC. | $624.12 | 2020-2025 | Cimzia, Bimzelx |
| Amgen INC. | $573.48 | 2019-2025 | Krystexxa, Avsola, Amjevita |
| Horizon Therapeutics Plc | $439.19 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $358.53 | 2021-2023 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $195.13 | 2019-2024 | |
| Lilly USA, LLC | $179.98 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $168.93 | 2020-2021 | |
| Glaxosmithkline, LLC. | $166.72 | 2019-2021 | |
| Genzyme Corporation | $151.47 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $146.59 | 2019-2025 | |
| Radius Health, INC. | $140.89 | 2024-2025 | Tymlos |
| Organon LLC | $97.31 | 2023-2024 | Renflexis, Hadlima |
| Pfizer INC. | $79.45 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $49.59 | 2023 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $44.90 | 2020-2021 | |
| Octapharma USA, INC. | $37.82 | 2022 | |
| Sandoz INC. | $28.82 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.75 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $24.47 | 2020 | |
| Mallinckrodt Enterprises LLC | $24.04 | 2019 | |
| Recordati_rare_diseases_inc. | $23.35 | 2023 | Sylvant |
| Takeda Pharmaceuticals U.S.A., INC. | $22.98 | 2022 | |
| Scilex Pharmaceuticals INC. | $22.23 | 2024 | |
| Tersera Therapeutics LLC | $21.67 | 2021 | |
| Genentech USA, INC. | $18.68 | 2024 | Actemra |
| Merck Sharp & Dohme LLC | $18.03 | 2019 | |
| Hikma Pharmaceuticals USA | $12.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manmohan Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.